News

Filter

Current filters:

Boehringer Ingelheim

151 to 160 of 1235 results

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta

03-06-2013

Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

Boehringer Ingelheim gets FDA warning letter on cGMP failures

22-05-2013

German family-owned drug major Boehringer Ingelheim today (May 22) revealed that the US Food and Drug…

Boehringer IngelheimGenericsPharmaceuticalProductionRegulation

Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

17-05-2013

German family-owned drug major Boehringer Ingelheim said today (May 17) that it is updating health care…

Boehringer IngelheimCombivent RespimatManagementPharmaceuticalProductionRespiratory and Pulmonary

US FDA approves companion diagnostic for Tarceva, and new indication for the Roche drug

15-05-2013

The US Food and Drug Administration late yesterday (May 14) approved Swiss drug major Roche (ROG: SIX)…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationRocheTarcevaTomtovok

Surveys reveal opportunity for medical community to fully embrace biomarker testing in lung cancer

07-05-2013

Results of two surveys that explored how pulmonologists and pathologists are incorporating biomarker…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalResearch

Boehringer Ingelheim joins SGC for further research into incurable diseases

06-05-2013

German family-owned drug major Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC),…

Boehringer IngelheimPharmaceuticalRare diseasesResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Boehringer Ingelheim Venture Fund invests in Eyevensys

15-04-2013

Paris, France-based Eyevensys, a developer of a new process for non-viral gene therapy using electrotransfer…

Boehringer IngelheimEyevensysFinancialMergers & AcquisitionsOphthalmicsPharmaceutical

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018

10-04-2013

US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

151 to 160 of 1235 results

Back to top